halothane has been researched along with Neuroleptic Malignant Syndrome in 13 studies
Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The in vitro halothane and caffeine contracture tests have been performed on muscle tissue from six survivors of the neuroleptic malignant syndrome." | 7.67 | Neuroleptic malignant syndrome and malignant hyperthermia. In vitro comparison with halothane and caffeine contracture tests. ( Adnet, P; Guevart, E; Krivosic-Horber, R; Lestavel, P; Theunynck, D, 1987) |
| " Following initial improvement, she developed delayed rhabdomyolysis then haloperidol-induced neuroleptic malignant syndrome, which was treated with a total of 50 mg." | 3.78 | Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene. ( Hawryluck, LA; Kraeva, N; Riazi, S; Russell, T; Steel, AC, 2012) |
| " Eight days later, he presented with a neuroleptic malignant syndrome following an injection of droperidol." | 3.70 | Malignant hyperthermia and neuroleptic malignant syndrome in a patient during treatment for acute asthma. ( Cardinaud, JP; Favier, JC; Gbikpi-Benissan, G; Gruson, D; Hilbert, G; Portel, L, 1999) |
| " Diagnosis is based on in vitro muscle contracture in response to halothane and/or caffeine exposure." | 3.70 | [Malignant hyperthermia susceptibility in 3 patients with malignant neuroleptic syndrome]. ( Bahia, VS; Marchiori, PE; Oliveira, RA; Scaff, M; Silva, HC; Tsanaclis, AM, 2000) |
| " The in vitro halothane-caffeine contracture tests are the most reliable method of identifying individuals susceptible to MH." | 3.67 | The association between the neuroleptic malignant syndrome and malignant hyperthermia. ( Adamantidis, MM; Adnet, PJ; Adnet-Bonte, CA; Dupuis, BA; Haudecoeur, G; Krivosic-Horber, RM; Saulnier, F, 1989) |
| "The in vitro halothane and caffeine contracture tests have been performed on muscle tissue from six survivors of the neuroleptic malignant syndrome." | 3.67 | Neuroleptic malignant syndrome and malignant hyperthermia. In vitro comparison with halothane and caffeine contracture tests. ( Adnet, P; Guevart, E; Krivosic-Horber, R; Lestavel, P; Theunynck, D, 1987) |
| "Malignant hyperthermia is a hypermetabolic syndrome that appears in susceptible patients after exposure to certain anaesthetic drugs (succinylcholine, inhalation anaesthetics)." | 2.55 | Clinical protocol for the management of malignant hyperthermia. ( Alsina, E; Del Blanco, B; Domínguez, A; García, A; Guerrero, JL; Kollmann-Camaiora, A; Yepes, MJ, 2017) |
| "Pretreatment with bromocriptine conferred no protection against the syndrome." | 1.28 | Porcine stress syndrome: an animal model for the neuroleptic malignant syndrome? ( Keck, PE; McElroy, SL; Pope, HG; Seeler, DC, 1990) |
| "The relationship between neuroleptic malignant syndrome (NMS) and malignant hyperthermia (MH) was investigated using the in vitro skeletal muscle contracture test to screen for MH-susceptibility in NMS patients." | 1.27 | Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. ( Caroff, SN; Fletcher, JE; Heiman-Patterson, TD; Mann, SC; Rosenberg, H, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kollmann-Camaiora, A | 1 |
| Alsina, E | 1 |
| Domínguez, A | 1 |
| Del Blanco, B | 1 |
| Yepes, MJ | 1 |
| Guerrero, JL | 1 |
| García, A | 1 |
| Russell, T | 1 |
| Riazi, S | 1 |
| Kraeva, N | 1 |
| Steel, AC | 1 |
| Hawryluck, LA | 1 |
| Bello, N | 1 |
| Adnet, P | 3 |
| Saulnier, F | 2 |
| Lestavel, P | 2 |
| Adnet-Bonte, C | 1 |
| Reyford, H | 2 |
| Etchrivi, T | 1 |
| Tavernier, B | 1 |
| Krivosic-Horber, R | 3 |
| Portel, L | 1 |
| Hilbert, G | 1 |
| Gruson, D | 1 |
| Favier, JC | 1 |
| Gbikpi-Benissan, G | 1 |
| Cardinaud, JP | 1 |
| Silva, HC | 1 |
| Bahia, VS | 1 |
| Oliveira, RA | 1 |
| Marchiori, PE | 1 |
| Scaff, M | 1 |
| Tsanaclis, AM | 1 |
| Adachi, Y | 1 |
| Wada, H | 1 |
| Higuchi, H | 1 |
| Watanabe, K | 1 |
| Satoh, T | 1 |
| Keck, PE | 1 |
| Seeler, DC | 1 |
| Pope, HG | 1 |
| McElroy, SL | 1 |
| Leys, D | 1 |
| Adamantidis, M | 1 |
| Dupuis, B | 1 |
| Mortier, W | 1 |
| Adnet, PJ | 1 |
| Krivosic-Horber, RM | 1 |
| Adamantidis, MM | 1 |
| Haudecoeur, G | 1 |
| Adnet-Bonte, CA | 1 |
| Dupuis, BA | 1 |
| Guevart, E | 1 |
| Theunynck, D | 1 |
| Caroff, SN | 1 |
| Rosenberg, H | 1 |
| Fletcher, JE | 1 |
| Heiman-Patterson, TD | 1 |
| Mann, SC | 1 |
| Addonizio, G | 1 |
| Susman, V | 1 |
2 reviews available for halothane and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
Clinical protocol for the management of malignant hyperthermia.
Topics: Adolescent; Adult; Caffeine; Calcium Signaling; Child; Child, Preschool; Clinical Protocols; Critica | 2017 |
Malignant hyperthermia: relation to other diseases.
Topics: Caffeine; Calcium Channels; Diagnosis, Differential; Halothane; Humans; Malignant Hyperthermia; Musc | 1990 |
11 other studies available for halothane and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene.
Topics: Anesthetics, Inhalation; Antipsychotic Agents; Body Temperature; Caffeine; Central Nervous System St | 2012 |
[Lack of sensitivity to per-anesthetic malignant hyperthermia in 32 patients who developed neuroleptic malignant syndrome].
Topics: Adolescent; Adult; Aged; Anesthesia, General; Caffeine; Contracture; Creatine Kinase; Dantrolene; Di | 1994 |
Malignant hyperthermia and neuroleptic malignant syndrome in a patient during treatment for acute asthma.
Topics: Acute Disease; Adjuvants, Anesthesia; Adult; Anesthetics, Inhalation; Asthma; Bronchodilator Agents; | 1999 |
[Malignant hyperthermia susceptibility in 3 patients with malignant neuroleptic syndrome].
Topics: Adult; Caffeine; Contracture; Disease Susceptibility; Female; Halothane; Humans; Male; Malignant Hyp | 2000 |
[The effect of halothane anesthesia on dopamine release induced by apomorphine or haloperidol--an in vivo microdialysis study in rats striatum].
Topics: Anesthesia, Inhalation; Anesthetics, Inhalation; Animals; Antipsychotic Agents; Apomorphine; Corpus | 2001 |
Porcine stress syndrome: an animal model for the neuroleptic malignant syndrome?
Topics: Animals; Brain; Bromocriptine; Disease Models, Animal; Haloperidol; Halothane; Hyperthermia, Induced | 1990 |
[Do neuroleptic malignant syndrome and malignant hyperthermia of anesthesia share a common mechanism?].
Topics: Caffeine; Halothane; Humans; Malignant Hyperthermia; Neuroleptic Malignant Syndrome | 1990 |
The association between the neuroleptic malignant syndrome and malignant hyperthermia.
Topics: Adult; Caffeine; Chlorpromazine; Contracture; Disease Susceptibility; Female; Halothane; Humans; Mal | 1989 |
Neuroleptic malignant syndrome and malignant hyperthermia. In vitro comparison with halothane and caffeine contracture tests.
Topics: Adult; Aged; Caffeine; Disease Susceptibility; Female; Halothane; Humans; In Vitro Techniques; Male; | 1987 |
Malignant hyperthermia susceptibility in neuroleptic malignant syndrome.
Topics: Adult; Disease Susceptibility; Female; Fluphenazine; Halothane; Humans; Male; Malignant Hyperthermia | 1987 |
Neuroleptic malignant syndrome and use of anesthetic agents.
Topics: Anesthetics; Halothane; Humans; Malignant Hyperthermia; Neuroleptic Malignant Syndrome; Succinylchol | 1986 |